Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives Why Is Barinthus Biotherapeutics Stock Trading Lower on Friday? - Barinthus Biotherapeutics (NASDAQ:BRNS)

Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.

Related Keywords

Barinthus Biotherapeutics , Nadege Pelletier , Barinthus Bio , William Blair , , Bill Enright , Chief Scientific Officer ,